Recovery from procedures to treat hypospadias is quite painful. With few downsides, CA is the most widely used, reliable, and safe regional approach in pediatric analgesia for such scenarios. However, high-concentration local anesthetic injections can raise the risk of motor weakness, delayed micturition, or urinary retention (
16,
17). This randomized prospective study focused on the recovery and analgesic characteristics of intravenous dexmedetomidine when compared to CA and general anesthesia in pediatric patients undergoing hypospadias surgery repair.
Until now, no study has discussed the effects of the caudal block versus IV dexmedetomidine on improving the quality of pain and emergency after hypospadias repair in detail.
In this study, postoperative pethidine dose was higher in patients receiving GA than in the caudal and Group Ds, with no significant difference between the caudal and dexmedetomidine groups. Moreover, patients receiving dexmedetomidine were extubated significantly later than those in the control and caudal groups.
Regarding MOPS, crying, movements, postures, and agitation, this study showed a significant difference between Group C and the other two groups 30 minutes and one hour after operation for movements, postures, and agitation.
Following Li et al., 90 patients undergoing elective open gastrectomy under TIVA in this study were divided into three groups: The control group received a placebo, the epidural group (Group E) received epidural anesthesia, and Group D received IV dexmedetomidine 0.6 μg/kg before the induction of general anesthesia, followed by dexmedetomidine 0.4 μg/kg/h until peritoneal closure (
18). Group D had a lower agitation rate (6.7%) that Group C (26.6%) (P = 0.038). In contrast to our findings, Li et al. found that the time of tracheal extubation was the same across all groups (
18).
Ninety children were randomly divided into three groups and given normal saline (Group S), dexmedetomidine 0.5 μg/kg (Group D 0.5), or dexmedetomidine 1 μg/kg (Group D1). Bhat et al. evaluated the effectiveness of two doses of dexmedetomidine on laryngeal mask airway removal (
19). They reported that dexmedetomidine 1 μg/kg was more effective than 0.5 μg/kg in reducing emergence agitation (
19).
Our findings are consistent with those reported by Guler et al., who carried out a comparable trial on children and similarly concluded that dexmedetomidine 0.5 mg/kg facilitates smooth extubation and lessens agitation following sevoflurane anesthesia in children with adenotonsillectomy (
20). We discovered that the time to emergence was substantially longer in the dexmedetomidine 0.5 μg/kg group (9.30 ± 2.9 min) compared to the placebo group (7.20 ± 2.7 min) (
20). Similar findings were presented in our study, which can be explained by the sedative effects of dexmedetomidine. Kim et al. also concluded that intraoperative dexmedetomidine administration at 0.4 μg/kg provided stable hemodynamic emergence (
21).
Furthermore, Bindu et al. documented that dexmedetomidine 0.5 μg/kg considerably decreased the emergence time and recovery time, hypothesizing that a reduction in the intraoperative need for sevoflurane might have caused an earlier waking (
22).
Yang et al. concluded that dexmedetomidine enhances recovery quality and reduces emergence agitation in their systematic review and meta-analysis on the effects of dexmedetomidine on decreasing emergence agitation in children following various types of procedures under general anesthesia (
23).
Many studies support the analgesic benefits of dexmedetomidine. Children with an intraoperative dexmedetomidine infusion after hypospadias correction surgery had considerably reduced pain and behavior scores in the PACU, according to Patel et al., as both the number of patients in the PACU who needed morphine and asked for it significantly decreased (
24).
Dexmedetomidine was found to be more effective than fentanyl in reducing postoperative pain scores and the number of rescue doses of morphine in a trial on children with obstructive sleep apnea after tonsillectomy and adenoidectomy. Even after surgery, dexmedetomidine’s analgesic and opioid-sparing effects were still clearly observed; the patients receiving dexmedetomidine required analgesics much later in the course of treatment (
25).
When evaluating postoperative agitation in children with lumbosacral spinal dysraphism, who were randomly randomized to receive either dexmedetomidine or a placebo, Gupta et al. reached a different finding (
26). There was no appreciable variation between the two groups’ emergence and extubation time. However, postoperatively, the kids in Group D had markedly lower pain levels and agitation scores, coupled with a more extended period of initial analgesic necessity, which was consistent with the present findings (
26).
Inconsistent findings are re reported in the literature on delays in the emergence and prolongation of extubation time when dexmedetomidine is used during the intraoperative period. Peng and Zhang illustrate that 0.5 μg/kg/h dexmedetomidine does not prolong extubation time, while one μg/kg/h may prolong extubation time (
27). Furthermore, Al-Zaben et al. discussed the effect of dexmedetomidine vs. saline on recovery time regarding respiratory recovery time, extubation time, spontaneous eye-opening time, spontaneous arm or leg motion time, and the time of discharge to the PACU and concluded that dexmedetomidine did not prolong recovery time (
28).
Other investigations failed to find evidence on the longer emergence or discharge time (
29-
31). This inconsistency might have been caused by different doses, variable administration route, or timing of the dexmedetomidine and other opioids (
19).
Although there was a tendency toward the lower incidence of these two postoperative complications in Group D, this study found no discernible difference in the incidence of coughs and PONV between the groups. The fact that both groups received ondansetron as an antiemetic and used less perioperative fentanyl can be blamed for the negligible difference in the incidence of PONV. For example, mouth dryness was more prevalent in Group D than in the control group in a trial study by Bajwa et al.; this medication protected against nausea, vomiting, and headache (
32).
Similarly, Kim et al. found that dexmedetomidine 0.4 μg/kg/h offered no further benefit in reducing coughing (
21).
Gupta et al. discovered that Group D revealed a considerably decreased incidence of postoperative nausea and vomiting (11.1% vs. 50%) (
26).
On the other hand, most of our cases in the control group developed shivering postoperatively without a significant difference when compared to the caudal and dexmedetomidine groups at P = 0.306. Dexmedetomidine can be useful in controlling the shivering mechanism because it lowers the temperature threshold for shivering. Dexmedetomidine’s ability to reduce vasospasm and the effect of the agonist alpha-2 are two additional potential pathways in preventing shivering (
33).
Regarding tachycardia, a significantly higher number of patients in the control group (66.7%) developed tachycardia when compared to the caudal and dexmedetomidine groups (20% and 22.2%, respectively, P < 0.001). This is reinforced by the fact that in animal research, dexmedetomidine inhibits epinephrine/halothane-induced ventricular tachycardia, and this putative antiarrhythmic function is associated with cerebral imidazoline receptors (
34).
According to Li et al., after starting dexmedetomidine, the heart rate in group D decreased significantly and stayed significantly lower throughout the surgical procedure (P < 0.0001 for all groups) (
18).
Unfortunately, there were several limitations in this study. The sevoflurane concentration was altered, precisely as in our trial, to keep the hemodynamic variables at their 20% baseline value. Accordingly, we could not evaluate the hemodynamic effects of dexmedetomidine single bolus dosages. Moreover, we did not compare the effects of various dexmedetomidine doses because we only employed one dose.
Furthermore, the study sample size is modest. We did not account for other issues while computing the sample size and only considered the decrease in MOPS. Despite these limitations, the study’s main strength is comparing the frequency and intensity of agitation using low dosages of dexmedetomidine not prolonging anesthetic recovery.
We can conclude that emergence benefits gained from the caudal block can be obtained by IV dexmedetomidine; however, it has less analgesic efficacy in pediatric patients undergoing hypospadias repair surgery without remarkable complications. Further clinical investigations are recommended to validate our findings.